164 related articles for article (PubMed ID: 37316954)
1. Subclassification of epithelioid sarcoma with potential therapeutic impact.
Haefliger S; Chervova O; Davies C; Nottley S; Hargreaves S; Sumathi VP; Amary F; Tirabosco R; Pillay N; Beck S; Flanagan AM; Lyskjaer I
J Pathol; 2023 Aug; 260(4):368-375. PubMed ID: 37316954
[TBL] [Abstract][Full Text] [Related]
2. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.
Kohashi K; Yamamoto H; Kumagai R; Yamada Y; Hotokebuchi Y; Taguchi T; Iwamoto Y; Oda Y
Mod Pathol; 2014 Jun; 27(6):832-9. PubMed ID: 24287458
[TBL] [Abstract][Full Text] [Related]
3. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
4. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
[TBL] [Abstract][Full Text] [Related]
5. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Yamada Y; Hotokebuchi Y; Yamamoto H; Taguchi T; Iwamoto Y; Oda Y
Hum Pathol; 2015 Feb; 46(2):225-30. PubMed ID: 25479928
[TBL] [Abstract][Full Text] [Related]
6. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.
Schaefer IM; Agaimy A; Fletcher CD; Hornick JL
Mod Pathol; 2017 Apr; 30(4):539-548. PubMed ID: 28084340
[TBL] [Abstract][Full Text] [Related]
7. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
8. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
9. The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms.
Dermawan JK; Singer S; Tap WD; Nacev BA; Chi P; Wexler LH; Ortiz MV; Gounder M; Antonescu CR
Mod Pathol; 2022 Dec; 35(12):1900-1909. PubMed ID: 36088476
[TBL] [Abstract][Full Text] [Related]
10. Re: Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor: Direct evidence of mutational inactivation of SMARCB1/INI1 in epithelioid sarcoma.
Flucke U; Slootweg PJ; Mentzel T; Pauwels P; Hulsebos TJ
Hum Pathol; 2009 Sep; 40(9):1361-2; author reply 1362-4. PubMed ID: 19683621
[No Abstract] [Full Text] [Related]
11. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions.
Sullivan LM; Folpe AL; Pawel BR; Judkins AR; Biegel JA
Mod Pathol; 2013 Mar; 26(3):385-92. PubMed ID: 23060122
[TBL] [Abstract][Full Text] [Related]
12. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
Andrianteranagna M; Cyrta J; Masliah-Planchon J; Nemes K; Corsia A; Leruste A; Holdhof D; Kordes U; Orbach D; Corradini N; Entz-Werle N; Pierron G; Castex MP; Brouchet A; Weingertner N; Ranchère D; Fréneaux P; Delattre O; Bush J; Leary A; Frühwald MC; Schüller U; Servant N; Bourdeaut F
J Pathol; 2021 Sep; 255(1):1-15. PubMed ID: 33999421
[TBL] [Abstract][Full Text] [Related]
13. Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma.
Del Savio E; Maestro R
Cells; 2022 Aug; 11(17):. PubMed ID: 36078034
[TBL] [Abstract][Full Text] [Related]
14. The genomic landscape of epithelioid sarcoma cell lines and tumours.
Jamshidi F; Bashashati A; Shumansky K; Dickson B; Gokgoz N; Wunder JS; Andrulis IL; Lazar AJ; Shah SP; Huntsman DG; Nielsen TO
J Pathol; 2016 Jan; 238(1):63-73. PubMed ID: 26365879
[TBL] [Abstract][Full Text] [Related]
15. SMARCB1-deficient Vulvar Neoplasms: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 14 Cases.
Folpe AL; Schoolmeester JK; McCluggage WG; Sullivan LM; Castagna K; Ahrens WA; Oliva E; Biegel JA; Nielsen GP
Am J Surg Pathol; 2015 Jun; 39(6):836-49. PubMed ID: 25651469
[TBL] [Abstract][Full Text] [Related]
16. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.
Le Loarer F; Zhang L; Fletcher CD; Ribeiro A; Singer S; Italiano A; Neuville A; Houlier A; Chibon F; Coindre JM; Antonescu CR
Genes Chromosomes Cancer; 2014 Jun; 53(6):475-86. PubMed ID: 24585572
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments.
Ngo C; Postel-Vinay S
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327458
[TBL] [Abstract][Full Text] [Related]
18. Utility of characteristic 'Weak to Absent' INI1/SMARCB1/BAF47 expression in diagnosis of synovial sarcomas.
Rekhi B; Vogel U
APMIS; 2015 Jul; 123(7):618-28. PubMed ID: 25912315
[TBL] [Abstract][Full Text] [Related]
19. Primary adult sellar SMARCB1/INI1-deficient tumor represents a subtype of atypical teratoid/rhabdoid tumor.
Duan Z; Yao K; Yang S; Qu Y; Ren M; Zhang Y; Fan T; Zhao H; Gao J; Feng J; Fan X; Qi X
Mod Pathol; 2022 Dec; 35(12):1910-1920. PubMed ID: 35804041
[TBL] [Abstract][Full Text] [Related]
20. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]